NADK and neoplasm: Yau et al. performed the CRISPR-Cas9 screening in human KRAS mutant CRC cells, and found that genetic or pharmacologic disruption of the metabolic enzymes nicotinamide adenine dinucleotide kinase (NADK) or ketohexokinase inhibited tumor growth in vivo, indicating that NADK inhibitors can be promising candidates for combinational therapy (161).